Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.
2.
3.

Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults.

Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, Delagarza VW, Bennett R, Chanock RM, Murphy BR, Clements-Mann ML, Falsey AR.

Vaccine. 2000 Mar 6;18(17):1763-72.

PMID:
10699324
4.

Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis.

Piedra PA, Grace S, Jewell A, Spinelli S, Hogerman DA, Malinoski F, Hiatt PW.

Pediatr Infect Dis J. 1998 Mar;17(3):217-24.

PMID:
9535249
5.

Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.

Piedra PA, Grace S, Jewell A, Spinelli S, Bunting D, Hogerman DA, Malinoski F, Hiatt PW.

Pediatr Infect Dis J. 1996 Jan;15(1):23-31.

PMID:
8684872
6.

Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.

Tristram DA, Welliver RC, Mohar CK, Hogerman DA, Hildreth SW, Paradiso P.

J Infect Dis. 1993 Jan;167(1):191-5.

PMID:
8418166
7.

Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection.

Piedra PA, Glezen WP, Kasel JA, Welliver RC, Jewel AM, Rayford Y, Hogerman DA, Hildreth SW, Paradiso PR.

Vaccine. 1995 Aug;13(12):1095-101.

PMID:
7491817
8.
10.

A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.

Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, Li M, Capellan J, Wang E.

Vaccine. 2009 Sep 25;27(42):5913-9. doi: 10.1016/j.vaccine.2009.07.038. Epub 2009 Aug 3.

PMID:
19651171
11.

Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis.

Piedra PA, Cron SG, Jewell A, Hamblett N, McBride R, Palacio MA, Ginsberg R, Oermann CM, Hiatt PW; Purified Fusion Protein Vaccine Study Group.

Vaccine. 2003 Jun 2;21(19-20):2448-60.

PMID:
12744878
12.
13.

Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines.

Simoes EA, Tan DH, Ohlsson A, Sales V, Wang EE.

Vaccine. 2001 Dec 12;20(5-6):954-60.

PMID:
11738763
16.

Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old.

Paradiso PR, Hildreth SW, Hogerman DA, Speelman DJ, Lewin EB, Oren J, Smith DH.

Pediatr Infect Dis J. 1994 Sep;13(9):792-8.

PMID:
7808848
17.

Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA.

Am J Trop Med Hyg. 2000 Jun;62(6):681-5.

PMID:
11304054
18.

Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children.

Karron RA, Wright PF, Crowe JE Jr, Clements-Mann ML, Thompson J, Makhene M, Casey R, Murphy BR.

J Infect Dis. 1997 Dec;176(6):1428-36.

PMID:
9395351
19.

Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine.

Welliver RC, Tristram DA, Batt K, Sun M, Hogerman D, Hildreth S.

J Infect Dis. 1994 Aug;170(2):425-8.

PMID:
8035030

Supplemental Content

Support Center